



Media Contact: Rhonda Madaris  
13794 NW 4th Street  
Suite 212  
Sunrise, FL 33325  
Telephone 954-835-1500  
Email:rmadaris@bioheartinc.com

**For Immediate Release**

**BIOHEART IN PARTNERSHIP WITH NORTHSTAR TO  
SUBSIDIZE PHYSICIAN TRAINING IN STEM CELL  
TECHNIQUES**

---

Sunrise, FL – December X, 2012 - Bioheart Inc. (BHRT.QB) previously announced that it is working with NorthStar Biotech to help promote regenerative medicine. NorthStar has announced that it will subsidize physicians to participate in the Ageless Regenerative Institute stem cell training program. The fully accredited CME training program includes a didactic lecture series followed by hands-on clinical training for physicians to learn to isolate stem cells for immediate use in their patients. The Ageless Regenerative Institute has been training physicians in stem cell techniques for over 2 years and has successfully trained over 200 physicians. These physicians are utilizing both adipose and bone marrow derived stem cells as well as platelet rich plasma for orthopedics, aesthetics and other degenerative diseases.

With the new NorthStar/Bioheart program, a select group of physicians have the opportunity to receive full funding for the training and join a network of physicians who will offer in clinic stem cell therapies. The first group of chosen physicians completed

-MORE-

training in November and will begin to implement these protocols into their well-known orthopedic practice in Miami.

**Do you think we could put a quote from one of Docs? Maybe Blanco?**

Bioheart's president and CEO, Mike Tomas said, "The training programs at the Ageless Regenerative Institute provide physicians with extraordinary regenerative medicine capabilities. We are fortunate to partner with Northstar to bring these therapies to the clinic."

Physicians interested in applying to participate in the program should contact Kristin Comella at [info@agelessregen.com](mailto:info@agelessregen.com).

### **About Bioheart, Inc.**

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit [www.bioheartinc.com](http://www.bioheartinc.com), or visit us on Facebook: Bioheart and Twitter @BioheartInc.

### **About Ageless Regenerative Institute, LLC**

The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research. ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple

indications, and more. ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy. For more information about regenerative medicine please visit [www.agelessregen.com](http://www.agelessregen.com).

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.